% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Djaileb:305583,
      author       = {L. Djaileb and A. Farolfi and I. Rauscher and M.
                      Haghighatian and A. Mercier and W. P. Fendler$^*$ and B.
                      Hadaschik$^*$ and K. Herrmann$^*$ and L. B. Solnes and M.
                      Rettig and M. Weber$^*$ and J. Czernin and J. Calais and M.
                      R. Benz and M. Eiber and A. Gafita},
      title        = {{C}linical {I}mpact of {C}hanges in {T}umor {U}ptake and
                      {V}olume on {PSMA} {PET}/{CT} {D}uring [177{L}u]{L}u-{PSMA}
                      {T}herapy in {M}etastatic {C}astration-{R}esistant
                      {P}rostate {C}ancer.},
      journal      = {Journal of nuclear medicine},
      volume       = {nn},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2025-02242},
      pages        = {nn},
      year         = {2025},
      note         = {epub / brief communication},
      abstract     = {Although tumor volume and new lesions (NLs) have been
                      investigated previously as measures of response, the
                      clinical impact of changes in tumor uptake on
                      prostate-specific membrane antigen (PSMA) PET remains
                      largely unknown. Methods: This multicenter retrospective
                      study investigated the clinical impact of changes in tumor
                      uptake and volume on PSMA PET during [177Lu]Lu-PSMA in
                      metastatic castration-resistant prostate cancer (mCRPC). The
                      primary outcomes were the associations of changes in SUVmax
                      (ΔSUVmax) and SUVmean (ΔSUVmean), changes in total tumor
                      volume (ΔTTV), and occurrence of NLs with prostate-specific
                      antigen (PSA) progression-free survival (PSA-PFS) and
                      overall survival (OS). The study included patients with
                      mCRPC who received [177Lu]Lu-PSMA between 2014 and 2019.
                      PSMA PET/CT was performed at baseline and after 2 cycles of
                      therapy. Whole-body analyses (SUVmax, SUVmean, TTV, and NLs)
                      were performed and calculated using qPSMA software. Results:
                      In total, 124 patients with mCRPC (median age, 73 y;
                      interquartile range, 67-76 y) were included in the study.
                      Whole-body ΔTTV and the occurrence of NLs were
                      significantly associated with shorter PSA-PFS (hazard ratio
                      [HR], 5.7; $95\%$ CI, 3.59-9.06; and HR, 1.6; $95\%$ CI,
                      1.4-1.8; P < 0.0001) and with OS (HR, 2.3; $95\%$ CI,
                      1.61-3.43; and HR, 1.3; $95\%$ CI, 1.1-1.4; P < 0.001).
                      Patient-based analysis showed that ΔSUVmax and ΔSUVmean
                      were not associated with outcome (HR, 1.00; $95\%$ CI,
                      0.99-1.00; P = 0.30; and HR, 0.90; $95\%$ CI, 0.99-1.00; P =
                      0.11). Region-based analysis found that only ΔSUVmax in
                      visceral lesions was significantly associated with PSA-PFS
                      (P = 0.007) but not with OS. Conclusion: Only ΔTTV and the
                      occurrence of NLs provided significant prognostic value and
                      should be considered when evaluating treatment response to
                      [177Lu]Lu-PSMA therapy.},
      keywords     = {LuPSMA (Other) / PSMA PET (Other) / RECIP (Other) /
                      metastatic castration-resistant prostate cancer (Other) /
                      radiopharmaceutical therapy (Other) / response evaluation
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41167722},
      doi          = {10.2967/jnumed.125.270239},
      url          = {https://inrepo02.dkfz.de/record/305583},
}